Concepedia

Wenyuan Xiong

WX

4

Publications

158

Citations

4

H-Index

2019

Active since

Affiliations

Merck (Germany)(Current)

The University of Texas MD Anderson Cancer Center

Research & Development Institute

Ono Pharmaceutical (United States)

Merck Serono (Switzerland)

Wenyuan Xiong is an author at Merck (Germany).

Publications per year

2019–2022

4

Publications

4

First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors

Gerald S. Falchook, Razelle Kurzrock, Hesham M. Amin et al. · Clinical Cancer Research · 2019 · 86 citations · Full text

Translational pharmacokinetic‐pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose

Wenyuan Xiong, Manja Friese‐Hamim, Andreas Johne et al. · CPT Pharmacometrics & Systems Pharmacology · 2021 · 32 citations · Full text

Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer

Apostolia M. Tsimberidou, Jamie Shaw, Dejan Juric et al. · Journal of Hematology & Oncology · 2021 · 28 citations · Full text

Exposure–response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendations

Wenyuan Xiong, Sofia Friberg Hietala, Joakim Nyberg et al. · Cancer Chemotherapy and Pharmacology · 2022 · 12 citations · Full text

Rows per page

1–4 of 4